Mark Vincent
Director/Board Member at APTOSE BIOSCIENCES INC.
Net worth: 502 $ as of 2024-04-29
Mark Vincent active positions
| Companies | Position | Start | End |
|---|---|---|---|
| APTOSE BIOSCIENCES INC. | Director/Board Member | 2007-09-18 | - |
| Independent Dir/Board Member | 2007-09-18 | - | |
| Sarissa, Inc. | Director/Board Member | 2011-01-17 | - |
| Chief Executive Officer | 1999-12-31 | - | |
| Founder | 1999-12-31 | - | |
| University of Western Ontario | Corporate Officer/Principal | 2007-12-31 | - |
Career history of Mark Vincent
Former positions of Mark Vincent
| Companies | Position | Start | End |
|---|---|---|---|
DRI Capital, Inc.
 DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Director/Board Member | - | - |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | 1999-12-31 | - |
Training of Mark Vincent
| University of Cape Town | Doctorate Degree |
Statistics
International
| Canada | 4 |
| United Kingdom | 2 |
| United States | 2 |
Operational
| Director/Board Member | 3 |
| Corporate Officer/Principal | 2 |
| Chief Executive Officer | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| APTOSE BIOSCIENCES INC. | Health Technology |
| Private companies | 3 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
| Sarissa, Inc. | |
DRI Capital, Inc.
DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Finance |
- Stock Market
- Insiders
- Mark Vincent
- Experience
